health
Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session

CHENGDU, China, Sept. 22, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Multiple Phase III clinical studies of the TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®)...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories

Overprescribing can take a toll on older peoples’ health and independence - here’s what can be done
The Conversation

Only 2pc can spot signs of common heart risk
New England Times
Victoria’s Dedicated Health Workforce Deliver Record Care
The National Tribune
New Program to Fast-Track Provincial Clinical Trials
Mirage News

Oral HRT link with blood clots
Pharmacy Daily